Quick answers
- What is Indigotindisulfonate sodium used for?
- The FDA-approved label (Bludigo, Sagent Pharmaceuticals, July 20, 2026) says: “BLUDIGO is indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Indigotindisulfonate sodium have a boxed warning?
- No. None of the 2 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Indigotindisulfonate sodium?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Indigotindisulfonate sodium been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Indigotindisulfonate sodium?
- 2 companies list prescription products of Indigotindisulfonate sodium in the FDA NDC Directory, including Sagent Pharmaceuticals and Provepharm Inc..
What Indigotindisulfonate sodium is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
BLUDIGO is indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures. …
— FDA label: Bludigo, Sagent Pharmaceuticals, effective July 20, 2026. Read the full label on DailyMed →
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 2 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection |
|---|---|
| Route | Intravenous |
| Prescription products | 2 in the FDA NDC Directory |
| Brand names | Bludigo |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Sagent Pharmaceuticals1 product
- Provepharm Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA216264 BLUDIGO | Provepharm Sas | July 8, 2022 | 1, latest April 14, 2023 2023: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| SPL set ID of the quoted label | 2b91c39d-5f15-4dcf-9d3d-b378470e6bd7 |
|---|---|
| FDA labels (SPL) | 2 |
| FDA applications | NDA216264 |
| Active ingredients (FDA) | INDIGOTINDISULFONATE SODIUM |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Bludigo, Sagent Pharmaceuticals, effective July 20, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →